Stephan Christgau
Vorsitzender bei Venture Cup Foundation
Profil
Stephan Christgau is currently the Chairman of Venture Cup Foundation, Chairman of Octarine Bio IVS, Director of iSD Immunotech ApS, Director of IO Biotech ApS, Non-Executive Director of Scenic Biotech BV, Partner of Novo Seeds, and Managing Partner of Eir Ventures Danmark ApS.
He has formerly held positions such as Chairman of Thrombologic ApS, Chairman of Pcovery ApS, Chairman of Forendo Pharma Oy, Director of EpiTherapeutics ApS, Director of Inagen ApS, Director of Aros Pharma ApS, Director of Adenium Biotech ApS, Director of Acesion Pharma ApS, Director of Galecto Biotech ApS, Executive Director of Lysogene SA, Director of NMD Pharma A, Director of HepaRegeniX GmbH, Director of AFYX Therapeutics AS, and Investment Director of Novo Holdings A.
He has also worked as a Research Scientist at Novo Nordisk A and Senior Research Scientist at Osteometer Biotech AS and Immunodiagnostic Systems Nordic A.
Dr. Christgau holds a doctorate degree from The University of California, San Francisco and a graduate degree from Technical University of Denmark.
Aktive Positionen von Stephan Christgau
Unternehmen | Position | Beginn |
---|---|---|
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 10.08.2009 |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - |
Venture Cup Foundation | Vorsitzender | - |
Octarine Bio IVS
Octarine Bio IVS BiotechnologyHealth Technology Octarine Bio IVS engages in the development of cannabinoid and psychedelic tryptamine derivatives. Its other activities include synthetic biology research. The company was founded by Nicholas Stuart William Milne on September 12, 2018 and is headquartered in Copenhagen, Denmark. | Vorsitzender | 30.06.2020 |
Eir Ventures Danmark ApS | Private Equity Investor | 01.07.2020 |
iSD Immunotech ApS
iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Direktor/Vorstandsmitglied | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Stephan Christgau
Unternehmen | Position | Ende |
---|---|---|
GALECTO, INC. | Direktor/Vorstandsmitglied | 26.05.2021 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Vorsitzender | 01.07.2020 |
░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░ ░░░░░░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Stephan Christgau
The University of California, San Francisco | Doctorate Degree |
Technical University of Denmark | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
LYSOGENE | Commercial Services |
GALECTO, INC. | Health Technology |
Private Unternehmen | 24 |
---|---|
Osteologix, Inc. /Old/ | Health Technology |
Osteometer Biotech AS
Osteometer Biotech AS BiotechnologyHealth Technology Osteometer Biotech AS develops treatments for bone disorders. The private company is based in Herlev, Denmark and has subsidiaries in Denmark. | Health Technology |
Osteologix Holdings Plc
Osteologix Holdings Plc Pharmaceuticals: OtherHealth Technology Osteologix Holdings Plc engaged in the development of innovative pharmaceuticals for the treatment and prevention of bone and joint tissues diseases. The company was founded in October 2004 and was headquartered in Dublin, Ireland. | Health Technology |
Immunodiagnostic Systems Nordic A/S
Immunodiagnostic Systems Nordic A/S Medical SpecialtiesHealth Technology Immunodiagnostic Systems Nordic A/S develops diagnostic testing kits for clinical and research markets. It offers its services in the field of diagnostics of bone and cartilage diseases such as osteoporosis, bone metastasis, arthritis, and osteoarthritis. The firm produces bone markers and cartilage markers, besides providing testing services. The company was founded on November 1, 1992 and is headquartered in Copenhagen, Denmark. | Health Technology |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Inagen ApS
Inagen ApS Miscellaneous Commercial ServicesCommercial Services Inagen ApS is a holding company that develops novel biopharmaceuticals for anti-viral treatment opportunities. Its primary candidate is treatment for Cytomegalovirus (CMV). The technology utilizes a "self targeting capability", which takes place in the natural defense mechanism of the specific disease, to target and kill infected cells. Its platform technology can be utilized to target numerous infectious diseases. The company was founded by Thomas Nitschke Kledal l in 2007 and is headquartered in Lyngby, Denmark. | Commercial Services |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Finance |
Venture Cup Foundation | |
Thrombologic ApS
Thrombologic ApS Miscellaneous Commercial ServicesCommercial Services Thrombologic ApS provides medical research and develops therapeutics. The firm develops a new therapy for prevention and treatment of multiple organ failure in Intensive care unit (ICU) patients. The company was founded in December 2009 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Aros Pharma ApS
Aros Pharma ApS Pharmaceuticals: MajorHealth Technology Aros Pharma ApS is a holding company that develops medicine targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases, and immuno-suppressed patients. It is a biotech company that focuses on clinical development of a novel therapy for the treatment of gastrointestinal pain. The firm is developing a new pain relief therapy based on a small molecule (PPC-5650) that is a specific inhibitor of the ASIC 1a receptor (Acid Sensing Ion Channel subtype 1a). Its therapy is currently being tested in two phase I trials targeting pain in patients who suffer from Irritable Bowel Syndrome (IBS) or non-erosive Gastroesophageal Reflux Disease (NERD). The company was founded in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Health Technology |
Adenium Biotech ApS
Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
iSD Immunotech ApS
iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Health Technology |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Health Technology |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Commercial Services |
AFYX Therapeutics AS
AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Commercial Services |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
Octarine Bio IVS
Octarine Bio IVS BiotechnologyHealth Technology Octarine Bio IVS engages in the development of cannabinoid and psychedelic tryptamine derivatives. Its other activities include synthetic biology research. The company was founded by Nicholas Stuart William Milne on September 12, 2018 and is headquartered in Copenhagen, Denmark. | Health Technology |
Eir Ventures Danmark ApS | Finance |